Skip to main content
NewsPortfolioPress ReleasesPrintBio, Inc.Rapha Capital Management

PrintBio Reorganizes and Expands Leadership Team with Key Commercial and Market Development Appointments

By September 5, 2025No Comments

• Launches Hernia Division to Focus on Abdominal Wall Repair Solutions

• Strengthens Leadership to Drive Market Readiness for Surgical Innovation

These appointments, encompassing a remarkable depth of talent and industry experience for such a young company, demonstrates our commitment to bringing our truly novel solutions to market.”

— Dr. Kevin Slawin, Founder and CEO of PrintBio

LONG ISLAND CITY, NY, UNITED STATES, September 3, 2025 /EINPresswire.com/ — PrintBio announced today the creation of its Hernia Division, a dedicated business unit focused on delivering next-generation technologies for abdominal wall repair and reconstruction.

The PrintBio Hernia Division will unite the company’s leadership, clinical partners, and commercialization experts to spearhead the introduction of PrintBio’s groundbreaking 3D-printed mesh solutions. With an emphasis on surgeon engagement, value analysis pathways, and hospital adoption, the division will serve as the cornerstone of PrintBio’s market-entry strategy.

“The formation of the Hernia Division reflects our commitment to transforming surgical repair with technologies that address real-world challenges faced by surgeons and hospitals,” said Dr. Kevin Slawin, Chairman and CEO of PrintBio. “We are investing in the infrastructure, people, and processes needed to support a successful launch and sustained growth in this category.”

The Hernia Division will be representing PrintBio at the American Hernia Society Annual Meeting in Nashville, September 4–6, 2025, where the company will introduce its first of a kind programmable mesh, DynaFlex™ Programmable Surgical Mesh (PSM), incorporating its revolutionary MetaDirectional Flex™ Technology.

Along with this reorganization, PrintBio also announced today the expansion of its leadership team to accelerate its next phase of growth in surgical innovation. The company has appointed Stephen Pinto as Vice President, Commercial Strategy and Sue Woodring as Director, Sales Infrastructure and Enablement.

• Stephen Pinto brings extensive expertise in commercial strategy and life sciences marketing, with a proven track record of aligning innovative products to complex market needs.
• Sue Woodring will oversee the build-out of PrintBio’s sales infrastructure, encompassing ordering systems, customer service, and sales enablement tools critical to scaling commercialization.

“The combination of our reorganization and these appointments, encompassing a remarkable depth of talent and industry experience for such a young company, demonstrates our commitment to bringing our truly novel solutions to market,” said Dr. Kevin Slawin, Founder and CEO of PrintBio. “Together, Stephen and Sue strengthen our commercial leadership team and position PrintBio for long-term success.”

For additional information please visit the PrintBio website at www.printbio.com. To register additional interest, please fill out our Contact Form

Steve Pinto
PrintBio, Inc.
email us here

Rapha Capital Management, LLC is providing this website for informational purposes only. Nothing on this website is intended to constitute, or should be deemed to be, financial advisory, legal, tax, accounting or other professional advice to you or any other party; be an opinion of the appropriateness or suitability of any investment; or constitute an offer to sell or solicitation of an offer to buy any security or investment. This website and its content (collectively, “Content”) is intended for general informational purposes only and should not be acted upon without first obtaining financial advisory, legal, tax, accounting or other professional advice from your consultant or other professional with respect to your own personal investment objectives, financial circumstances and needs. Nothing on the Site shall be considered a recommendation or solicitation to buy or an offer to sell a security to any person in any jurisdiction where such offer, solicitation, purchase or sale would be unlawful under the securities laws of such jurisdiction. Any investment decisions you may make on the basis of any information found on this web site is your sole responsibility. Prior to making any investment or hiring any investment manager you should consult with a professional financial advisor, legal and tax advisor to assist in due diligence as may be appropriate and determining the appropriateness of the risk associated with a particular investment. In no event shall Rapha Capital Management, LLC be responsible or liable for the correctness of any such material or for any damage or lost opportunities resulting from use of these data.